MichaelThomasMassengillMDPhD

Physician

Dr. Massengill is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of Illinois College of Medicine at ChicagoResidency, Ophthalmology, 2020 - 2024
University of Florida College of MedicineClass of 2016

PubMed

Outcomes of Open-Globe Injuries With Associated Retinal Detachment: Experience at an Ocular Trauma Center.
Neil Sheth, Arthur Y Chang, John M Bryan, Michael T Massengill, Jennifer I Lim
Journal of Vitreoretinal Diseases. 2024-12-13
1 citations
Response of Diabetic Macular Edema to Anti-VEGF Medications Correlates with Improvement in Macular Vessel Architecture Measured with OCT Angiography.
Michael T Massengill, Samuel Cubillos, Neil Sheth, Abhishek Sethi, Jennifer I Lim
Ophthalmology Science. 2024-01-26
2 citations
Occult retinopathy following treatment of Hepatitis C with glecaprevir/pibrentasvir (Mavyret).
Michael T Massengill, Jason C Park, J Jason McAnany, Robert A Hyde
Documenta Ophthalmologica. Advances in Ophthalmology. 2023-04-01

Journal Articles

Clinically Relevant Outcome Measures for the I307N Rhodopsin Mouse: A Model of Inducible Autosomal Dominant Retinitis Pigmentosa
Michael Massengill, MD, Investigative Ophthalmology and Visual Science
Mutation-Independent Rhodopsin Gene Therapy by Knockdown and Replacement with a Single AAV Vector
Michael T Massengill, Samuel G Jacobson, Proceedings of the National Academy of Sciences